Abstract

TO STUDY THE PHARMACOLOGICAL PROFILE OF FOSFOMYCIN TROMETAMOL

Pravinya R. Sonkar*, Shubham V. Bhawar, Gauri N. Bhasme, Manva U. Bobde, Vedant D. Dhage, Dr. Manisha D. Kitukale*

Abstract

Urinary tract infections (UTIs) are among the most common bacterial infections worldwide and have become increasingly difficult to treat because of the growing problem of antimicrobial resistance. Fosfomycin Trometamol is a broad-spectrum phosphonic acid antibiotic that has gained renewed clinical importance due to its effectiveness against multidrug-resistant uropathogens. This review focuses on the pharmacological profile, mechanism of action, pharmacokinetics, therapeutic efficacy, safety, and clinical significance of Fosfomycin Trometamol. The drug acts by irreversibly inhibiting the MurA enzyme, thereby preventing bacterial cell wall synthesis and exhibiting potent bactericidal activity. Fosfomycin Trometamol demonstrates favorable pharmacokinetic properties, including good oral bioavailability and prolonged urinary concentrations, making it suitable for single-dose therapy in uncomplicated urinary tract infections. The review also discusses its activity against resistant organisms, including ESBL-producing bacteria, and compares its resistance profile with other commonly used antimicrobial agents. In addition, formulation aspects, adverse effects, drug interactions, and use in special populations such as pregnant women and pediatric patients are summarized. The findings indicate that Fosfomycin Trometamol remains a safe, effective, and valuable therapeutic option in the management of urinary tract infections and plays an important role in combating antimicrobial resistance.

Keywords: Fosfomycin Trometamol, Urinary Tract Infection (UTI), Antimicrobial Resistance, MurA Enzyme, Broad-Spectrum Antibiotic, Multidrug-Resistant Bacteria, Pharmacokinetics, ESBL-Producing Organisms, Single-Dose Therapy, Uropathogens.